Henagliflozin/metformin - Shandong Suncadia Medicine
Alternative Names: HR-20033; Metformin/SHR 3824 - Shandong Suncadia MedicineLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Shandong Suncadia Medicine
- Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Ethers; Fluorobenzenes; Glucosides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO, Tablet)
- 18 Jul 2024 Shandong Suncadia Medicine plans a phase I trial for Type 2 diabetes mellitus (In Volunteers) in China (PO) in July 2024 (NCT06495931)
- 05 Jul 2024 Launched for Type 2 diabetes mellitus (PO), prior to July 2024 (Jiangsu Hengrui Medicine pipeline, July 2024)